Evaluation of Mangoselect® in Improvement of Exercise/Activity-induced Knee Joint Discomfort in Subjects Suffering From Osteoarthritis Grade I or II
Launched by FYTEXIA · Feb 19, 2021
Trial Information
Current as of June 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Physically active volunteers
- • BMI 22-29.9 kg/m2
- • Declaring knee joint pain during and/or after activity/exercise
- • Joint knee pain rated of at least 4 cm on a 10 cm VAS following activity/exercise
- • Diagnosed osteoarthritis grade I or II according to Kellgren-Lawrence classification
- Exclusion Criteria:
- • Diagnosed inflammatory joint disorder or osteoarthritis grade III or more according to Kellgren-Lawrence classification
- • Currentlu chronically taking pain killer drugs or dietary supplement or intra-articular treatment 3 months before selection
- • Anemia
- • Subjects with knee/joint surgery/replacement in the past 10 years
- • Significant injury of the studied knee joint 12 months before selection
- • Unable to carry out functional tests and/or questionnaires
- • Currently participating or having participated in another clinical trial in the 3 previous months
- • Pregnant women and women positive at Beta-HCG serology test
- • Any condition that the investigator believes would interfere with the ability to provide inform consent, or comply with study instructions, or confound the interpretations of the study results, or put the volunteer at undue risk
- • Allergy to one of the component of the supplements
About Fytexia
Fytexia is a pioneering research and development company dedicated to the creation of innovative health solutions through the exploration of natural ingredients. With a strong focus on clinical trials and scientific validation, Fytexia harnesses cutting-edge methodologies to assess the efficacy and safety of its products, aimed at enhancing well-being across various health domains. The company is committed to advancing nutritional science and improving public health outcomes through rigorous research and collaboration with healthcare professionals and academic institutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Murcia, , Spain
Patients applied
Trial Officials
Pedro Alcaraz
Principal Investigator
UCAM (Universidad Catolica San Antonio de Murcia)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials